Restoration of branched-chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models
Graphical Abstract Sample Work
Patients with metabolic syndrome and heart failure (HF), frequently also have concurrent kidney dysfunction, which has recently been defined as cardiovascular-kidney-metabolic (CKM) syndrome. The plasma metabolomics profiling of patients with metabolic syndrome previously identified a plasma branched chain amino acid (BCAA) signature, and BCAAs are also elevated in the myocardium of patients with HF, presumably due to a disruption in the BCAA’s catabolic breakdown
Methods, intervention and results in three columns
This graphical abstract summarises a preclinical study by Bollinger and colleagues, published in Kidney International in 2025, showing that restoring branched-chain amino acid (BCAA) breakdown with the BDK inhibitor BT2 improved kidney function in rat models of cardiovascular-kidney-metabolic (CKM) syndrome. The layout is a three-column grid headed in italic bold: "Methods: Multiple pre-clinical CKM models", "Intervention: BT2 alone or in combination with SGLT2i" and "Results: BT2 monotherapy and combination with SGLT2i improved CKM parameters". Each heading is a full sentence, so a reader who scans only the column titles still receives the study's message.
The audience includes nephrology, cardiometabolic and pharmacology researchers.
BCAAs and the overlap of heart, kidney and metabolic disease
CKM syndrome describes the frequent co-occurrence of metabolic syndrome, heart failure and kidney dysfunction. Metabolomic studies of people with metabolic syndrome have identified a raised plasma BCAA signature, and BCAAs are also raised in the myocardium of patients with heart failure, probably because their catabolic breakdown is impaired.
The first committed step in BCAA catabolism is carried out by the branched-chain ketoacid dehydrogenase (BCKDH) complex. Branched-chain ketoacid dehydrogenase kinase (BDK) switches this complex off by phosphorylation. Inhibiting BDK therefore keeps BCKDH active and promotes BCAA breakdown. BT2 is a small-molecule BDK inhibitor, and SGLT2 inhibitors are already established treatments with kidney and cardiovascular benefits, which makes the combination clinically interesting.
Column one: two rat models and a metabolic rationale
The Methods column shows two animal models: the ZSF1 obese rat, a widely used model of metabolic syndrome with kidney and cardiac involvement, and the SDT rat with uninephrectomy (Unx) given high-salt water, a model designed to accelerate diabetic kidney injury. Below them, "Multi-omics profiling" leads to an equation-like line, "↑ BCAAs → CKM", flanked by red upward arrows, and the caption "Dysfunctional BCAA Breakdown". This compact sequence states the hypothesis before any intervention appears.
Showing the animals as simple, colour-differentiated illustrations rather than photographs keeps the column light, and naming each model in full beneath its icon matters because rat strains are not interchangeable. A reader familiar with the field will recognise immediately that the authors tested their idea in both an obesity-driven and a diabetes-driven setting, which is the main reason for including two models at all.
Column two: the compound and its target
The Intervention column draws BT2 as a chemical structure with an inhibition line pointing to a box labelled "Branched Chain Ketoacid Dehydrogenase Kinase (BDK)". Two downward arrows lead to a green upward arrow, indicating increased BCAA catabolism; this is labelled "BT2 monotherapy". Beneath, the same structure is shown with a plus sign and an SGLT2i bottle, labelled "BT2 + SGLT2i combination therapy". Repeating the molecular structure, rather than using a generic pill icon, signals to a specialist audience that the intervention is a defined small molecule.
Column three: histology, albuminuria and kidney mitochondria
The Results column combines several evidence types:
- Histology. Three glomerular micrographs at a 20 µm scale compare ZSF1 obese, obese-SGLT2i and obese-SGLT2i + BT2 groups, showing progressively less pathological change.
- Kidney mitochondria. A green upward arrow marks increased kidney mitochondrial density and function.
- Kidney damage. A green downward arrow marks reduced urine protein content, kidney hypertrophy and kidney pathological damage.
- Albumin/creatinine over time. A line graph from weeks 4 to 10 compares SD controls, SDT-sham, SDT-Unx, SDT-Unx with BT2 and SDT-Unx with SGLT2i, with significance asterisks showing that both treated groups diverge from untreated SDT-Unx animals.
An illustration combining a heart, kidneys and a glucose meter, labelled "Improved CKM", closes the column by returning to the syndrome as a whole.
Conclusion wording and how to adapt the format
The conclusion banner states that improving BCAA catabolic defects with BT2 can ameliorate CKM syndrome, and that BDK inhibitors "may show additional benefit" when given with SGLT2 inhibitors. The modal verb is appropriate for animal data, and preclinical studies of this type would follow ARRIVE reporting guidance. When adapting the format, check legends of embedded graphs: small labels copied from source figures (here, one group label reads "RT2") can carry typographical errors that should be corrected against the paper.
The sentence-style column headings are a useful device for any study with a clear method, intervention and result. Pubrica's graphical abstract service builds figures like this, and a simplified abstract can explain the same findings to non-specialist readers.
Questions about this sample
How does BT2 restore BCAA catabolism?
BT2 inhibits branched-chain ketoacid dehydrogenase kinase (BDK), the enzyme that switches off the BCKDH complex responsible for the key step in BCAA breakdown. With BDK inhibited, BCKDH stays active, and BCAAs are broken down more effectively. The figure shows this as an inhibition line from BT2 to BDK followed by an upward arrow.
Why are two different rat models shown?
The ZSF1 obese rat represents metabolic syndrome with heart and kidney involvement, while the SDT rat with uninephrectomy and high-salt water represents accelerated diabetic kidney injury. Testing BT2 in both models suggests that its effects are not limited to one experimental setting, which strengthens the preclinical case.
What does the albumin/creatinine graph show?
It tracks urinary albumin-to-creatinine ratio from weeks 4 to 10 across five groups. Untreated SDT-Unx animals show rising values, whereas animals treated with BT2 or an SGLT2 inhibitor stay lower, with asterisks marking a statistically significant difference. Albuminuria is a key marker of kidney damage in CKM syndrome.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
